Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatmentTheresia M. Westers, Arjan A. van de Loosdrecht, Canan Alhan et al.|Blood|2009Cited by 92
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndromeMartine E.D. Chamuleau, Arjan A. van de Loosdrecht, J. Groenland et al.|Haematologica|2009Cited by 72
Class II-Associated Invariant Chain Peptide Expression on Myeloid Leukemic Blasts Predicts Poor Clinical OutcomeMartine E.D. Chamuleau, Gert J. Ossenkoppele, Yuri Souwer et al.|Cancer Research|2004Cited by 63
Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortiumCristina Astrid Tentori, David A. Sallman, Lin P. Zhao et al.|HemaSphere|2024Cited by 11